Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

Study acronym: DC-eALERT
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Lead sponsor: Brigham and Women's Hospital to Brigham and Women's Hospital Show 6 more changesShow less
    • Study completion pushed from Jun 30, 2026 to Dec 30, 2026
    • Secondary endpoints: details revised at 2 of 4 entries
    • Site details revised
    • Publications: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 3 words
    • Study description expanded, about 3 words
  2. Minor Study completion date: Dec 31, 2025 to Jun 30, 2026v10
  3. Minor Study completion date: Dec 31, 2024 to Dec 31, 2025v9
  4. Minor Study completion date: Dec 31, 2023 to Dec 31, 2024v8
  5. Minor Primary completion date changed from estimate of Sep 30, 2022 to Dec 31, 2022
    • Study completion date: Dec 31, 2022 to Dec 31, 2023
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Notable Primary completion date: Nov 30, 2021 to Sep 30, 2022
    • Study completion date: Feb 1, 2022 to Dec 31, 2022
    v6
  2. Notable Primary completion date: Nov 30, 2020 to Nov 30, 2021
    • Study completion date: Feb 1, 2021 to Feb 1, 2022
    v5
  3. Notable Phase: Phase 4 to Not applicablev4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2018 to Feb 1, 2019
    v3
  5. Minor Secondary endpoints: details revised at 2 of 4 entriesv2
  1. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduced the frequency of asymptomatic proximal deep venous thrombosis (DVT), symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism (PE), or VTE-related death compared with short-duration enoxaparin. Obstacles to integration of these data in the hospitalized Medical Service patient population, including failure to identify at-risk patients, educational gaps in strategies for VTE prevention after discharge, and medication nonadherence, can be overcome with alert-based computerized decision support. This study is a single-center, 400-patient, randomized controlled trial of an EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase prescription of extended-duration post-discharge thromboprophylaxis and decrease symptomatic VTE in high-risk patients hospitalized with medical illness. Specific Aim #1: To determine the impact of electronic alert-based CDS (EPIC Best Practice Advisory \[BPA\]) on prescription of extended-duration post-discharge thromboprophylaxis in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge. Specific Aim #2: To estimate the impact of electronic alert-based CDS (EPIC BPA) on the frequency of symptomatic VTE in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge.
Trial Details
NCT Number NCT03728166
Lead Sponsor Brigham and Women's Hospital
Collaborators: Portola Pharmaceuticals
Conditions
(from sponsor)
Venous Thromboembolism
Related terms Venous Thromboembolism
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov